Alto Neuroscience Releases Q1 2026 Financial Results

[ad_1] AlphaStreet Newsdesk powered by AlphaStreet Intelligence ANRO|EPS -$0.80|Net Loss $26.2M Alto Neuroscience Inc reported a wider quarterly loss for the first three months of 2026, reflecting increased spending as the precision psychiatry company advances its clinical pipeline. The biotech…







